Sunday, April 5, 2026
Logo

Sarepta Therapeutics CEO Doug Ingram to retire after tumultuous decade

Ingram turned Sarepta into a $15 billion company by pushing treatments for Duchenne muscular dystrophy, then watched that value collapse.

BusinessBy Wire ServicesFebruary 26, 20261 min read

Last updated: April 4, 2026, 1:34 PM

Share:
Sarepta Therapeutics CEO Doug Ingram to retire after tumultuous decade

Ingram turned Sarepta into a $15 billion company by pushing treatments for Duchenne muscular dystrophy, then watched that value collapse.

WS
Wire Services

wire

Aggregated news from trusted wire services and news agencies worldwide.

Related Stories